[Gly14]-Humanin offers neuroprotection through glycogen synthase kinase-3β inhibition in a mouse model of intracerebral hemorrhage.
Wang. Tao T; Huang. Ya Y; Zhang. Mingyang M; Wang. Long L; Wang. Yaoqi Y; Zhang. Lu L; Dong. Wenwen W; Chang. Pan P; Wang. Zufeng Z; Chen. Xiping X; Tao. Luyang L
Key Findings
- HNG (2.5 µg IP) given 1 hour after induced brain bleed improved neurological scores and reduced brain edema in mice
- The peptide increased protective signals (p‑Akt, Bcl‑2) and lowered death signals (p‑GSK‑3β, cleaved caspase‑3, cleaved PARP)
- Blocking PI3K with wortmannin stopped HNG’s benefits, linking its action to the PI3K‑Akt/GSK‑3β pathway
Practical Outcomes
- While the results are promising for acute brain injury, they are limited to mice and involve a very small dose that can’t be directly translated to humans. Biohackers should view this as early‑stage evidence that humanin derivatives might protect the brain, but no safe or effective human dosing protocol exists yet. More research is needed before considering any self‑administration.
Summary
In a mouse study, a modified form of the peptide humanin (called HNG) given shortly after a brain bleed helped reduce swelling, shrink the damaged area, and improve movement and behavior. The benefit seems to come from turning on a cell‑survival pathway (PI3K‑Akt) and blocking a protein (GSK‑3β) that leads to cell death. The effect disappeared when a drug that blocks this pathway was used, confirming the mechanism.
Abstract
Perihematomal brain edema formation and consequent cell death contribute to second brain injury resulting in severe neurological deficits and sometimes delayed fatality after intracerebral hemorrhage (ICH). [Gly14]-Humanin (HNG), a variant of Humanin (HN) in which the 14th amino acid serine is replaced with glycine, reduced Alzheimer's disease-relevant insults and improved neurological deficits in an ischemia stroke model. In the study, we aimed to evaluate whether HNG posttreatment attenuated early brain injury after ICH and whether the protective effect was associated with regulation of apoptosis via phosphatidylinositol 3-kinase (PI3K)-Akt/GSK-3β signaling. Male ICR mice were subjected to infusion of Type IV collagenase (to induce ICH) of saline (for shams) into the left striatum. ICH animals received vehicle, HNG (1 or 2.5 μg in 100 μl saline) administration intraperitoneally 1h post injury. Compared with vehicle, HNG-2.5 μg treatment improved neurological outcome and reduced brain edema at 24 and 72 h after surgery (P<0.05), but wortmannin (15 μg/kg, 90 min before HNG-2.5 μg, intravenously) obliterated the effect. HNG-2.5 μg also reduced cell insults and injury volume at 24 and 72 h after surgery (P<0.05, vs. vehicle). Furthermore, HNG-2.5 μg treatment increased p-Akt and Bcl-2 and decreased p-GSK-3β, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase expressions in the ipsilateral hemisphere (P<0.05, vs. vehicle), however, the effect was reversed by wortmannin. In conclusion, HNG treatment improved functional and morphological outcomes after experimental ICH in mice and the protective effect was associated with suppressing apoptosis through PI3K-Akt/GSK-3β signaling pathway.
Study Information
pubmed
2013
2013-03-26T00:00:00.000Z
10.1016/j.bbr.2013.03.023
37
35